CTOs on the Move

Arete Pharmacy Network

www.areterx.com

 
American Associated Pharmacies and H. D. Smith combined respective pharmacy services administrative organizations (PSAO) into a new PSAO, servicing more than 2,300 independent retail pharmacies across the United States. Arete Pharmacy Network will combine and succeed H. D. Smith`s Third Party Network and AAP`s United Drugs. Arete Pharmacy Network focuses on independents and community pharmacies, with a focus on managed care contracting and expanded tools and services, allows pharmacies to deliver quality care as a differentiator in their communities. Arete Pharmacy Network can help effectively manage the financial, quality and operational aspects of your pharmacy business.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.areterx.com
  • 7243 North 16th Street
    Phoenix, AZ USA 85020
  • Phone: 866.709.1179

Executives

Name Title Contact Details

Similar Companies

Legacy Pharmaceuticals International

Legacy Pharmaceuticals International is a Humacao, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TCGRx

TCG employs a team of pharmacy designers and industrial engineers who can help with the integration of automation or storage and retrieval solutions that will meet the business needs of the pharmacy.

AAA Pharmaceutical

AAA Pharmaceutical is a Lumberton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fagen Pharmacy

Since the first Fagen Pharmacy was opened it has been my goal that each Fagen Pharmacy provides professional pharmaceutical services in a friendly and helpful environment. These were the principals I learned as young man and are still present today in

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.